Across TCGA pan-cancer cohorts, MEF2B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MEF2B data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MEF2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MEF2B expression acts as an unfavorable survival marker.

HNSC are the cancer types where MEF2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.089	0.737	<.001	11	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: MEF2B tumor-vs-normal RNA expression · all MEF2B data types